microcapdaily.com Open in urlscan Pro
35.197.12.90 Public Scan

Back to summary

Submitted URL:
https://t.notifications.meltwater.com/v2/3bbbf7f40ffb039d31d42336f50d1190?m=email&u=https%253A%252F%252Fmicrocapdaily.com%252Ft2-biosy...
Effective URL:
https://microcapdaily.com/t2-biosystems-nasdaq-ttoo-fda-expectations-and-speculation-around-the-next-memestock/
Submission: On August 23 via manual (August 23rd 2023, 4:21:09 am UTC) from IN — Scanned from DE

Form analysis
11 forms found in the DOM

GET https://microcapdaily.com/

<form method="get" id="searchform" action="https://microcapdaily.com/">
  <input type="text" name="s" id="s" value="Search" onfocus="if (this.value == &quot;Search&quot;) { this.value = &quot;&quot;; }" onblur="if (this.value == &quot;&quot;) { this.value = &quot;Search&quot;; }">
  <input type="hidden" id="searchsubmit" value="Search">
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST https://microcapdaily.com/wp-comments-post.php?wpe-comment-post=microcapdaily

<form action="https://microcapdaily.com/wp-comments-post.php?wpe-comment-post=microcapdaily" method="post" id="commentform" class="comment-form">
  <p class="comment-notes"><span id="email-notes">Your email address will not be published.</span> <span class="required-field-message">Required fields are marked <span class="required">*</span></span></p>
  <p class="comment-form-comment"><label for="comment">Comment <span class="required">*</span></label> <textarea id="comment" name="comment" cols="45" rows="8" maxlength="65525" required="required"></textarea></p>
  <p class="comment-form-author"><label for="author">Name <span class="required">*</span></label> <input id="author" name="author" type="text" value="" size="30" maxlength="245" autocomplete="name" required="required"></p>
  <p class="comment-form-email"><label for="email">Email <span class="required">*</span></label> <input id="email" name="email" type="text" value="" size="30" maxlength="100" aria-describedby="email-notes" autocomplete="email" required="required">
  </p>
  <p class="comment-form-url"><label for="url">Website</label> <input id="url" name="url" type="text" value="" size="30" maxlength="200" autocomplete="url"></p>
  <p class="comment-form-cookies-consent"><input id="wp-comment-cookies-consent" name="wp-comment-cookies-consent" type="checkbox" value="yes"> <label for="wp-comment-cookies-consent">Save my name, email, and website in this browser for the next time
      I comment.</label></p>
  <p class="form-submit"><input name="submit" type="submit" id="submit" class="submit" value="Post Comment"> <input type="hidden" name="comment_post_ID" value="41485" id="comment_post_ID">
    <input type="hidden" name="comment_parent" id="comment_parent" value="0">
  </p>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class=" snp-subscribeform snp_subscribeform">
  <input type="hidden" name="np_custom_name1" value="">
  <input type="hidden" name="np_custom_name2" value="">
  <fieldset>
    <div class="snp-field">
      <input type="email" name="email" id="snp_email" placeholder="Your E-mail..." class="snp-field snp-field-email">
    </div>
    <button type="submit" class="snp-submit">Subscribe Now</button>
  </fieldset>
</form>

POST #

<form action="#" method="post" class="snp-form snp-clearfix snp-subscribeform snp_subscribeform">
  <div class="snp-field snp-mail">
    <input type="text" name="email" id="snp_email" placeholder="ENTER YOUR EMAIL HERE" class="snp-field-email">
  </div>
  <button type="submit" data-loading="Please wait ..." data-success="Please wait ..." class="snp-btn snp-btnc snp-submit">Subscribe Now!</button>
</form>

Text Content

* Micro Cap Insider
* Media & Technology
* Emerging Markets
* Street Watch
* Small Caps
* About MCD
* Advertising
* Contact Us
* Privacy Policy
* SEC Disclosure

Connect with us
*
*

MICRO CAP DAILY

T2 BIOSYSTEMS (NASDAQ: TTOO): FDA EXPECTATIONS AND SPECULATION AROUND THE ‘NEXT
MEMESTOCK’

* Micro Cap Insider

* T2 Biosystems (NASDAQ: TTOO): FDA Expectations and Speculation Around the
‘Next Memestock’

* Novo Integrated Sciences (NASDAQ: NVOS) Gears Up for $57 Million RC Note
Disbursement

* Blue Apron Holdings (NASDAQ: APRN) Charts Path to Profitability in Q2
2023: Debt Elimination and Strategic Transaction

* PhenomeX Inc. (NASDAQ: CELL) to Merge with Bruker Corporation in Strategic
Acquisition

* Wheels Up Experience Inc. (NYSE: UP) to Exchange Majority Stock for $500
Million Lifeline Amid Financial Turmoil

* Media & Technology

* Mobilicom (NASDAQ: MOB) Secures Landmark Deal with Top Global Manufacturer

* Pagaya Technologies (NASDAQ: PGY) Experiences Astonishing Stock Surge:
From Struggling to Thriving

* Sientra Inc.’s (NASDAQ: SIEN) AlloX2 Pro Tissue Expander Rockets Shares
82%

* LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

* Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

* Emerging Markets

* Steakholder Foods (NASDAQ: STKH) Partners with GCC Government for
3D-Printed Food Revolution

* BioTech Medics, Inc. (OTC:BMCS) Boasts $70M in Assets and Transitions from
Crypto to BioTech

* Eastside Distilling (NASDAQ: EAST)Aims for Financial Turnaround: Debt
Restructuring Agreement Sparks 149% Gain in Share Value

* Auddia Inc.’s (NASDAQ: AUUD) Superapp Sets a New Standard

* Strong Financials and Social Media Buzz Propel Forza X1, Inc.
(NASDAQ:FRZA) to New Heights

* Street Watch

* T2 Biosystems (NASDAQ: TTOO): FDA Expectations and Speculation Around the
‘Next Memestock’

* Novo Integrated Sciences (NASDAQ: NVOS) Gears Up for $57 Million RC Note
Disbursement

* Wheels Up Experience Inc. (NYSE: UP) to Exchange Majority Stock for $500
Million Lifeline Amid Financial Turmoil

* WeWork Inc.’s (NYSE: WE) Astonishing Stock Surge: An Enigma Amidst
Bankruptcy Fears

* BIOLASE, Inc. (NASDAQ: BIOL) Takes Center Stage: Landmark Agreement with
Department of Defense

* Small Caps

* PhenomeX Inc. (NASDAQ: CELL) to Merge with Bruker Corporation in Strategic
Acquisition

* Yellow Corporation (NASDAQ: YELL): Bankruptcy Filing Sends Shockwaves
Through the Market – Unexpected Investor Surge

* Cracking the Code: Understanding Sympathy Plays and their Impact on Stocks
like Vroom Inc. (NASDAQ: VRM)

* Unlocking Potential: Biodexa Pharmaceutical’s (NASDAQ: BDRX) MTX110 Study
Progress Triggers Trading Frenzy

* Acquisition Interest on Root Inc. (NASDAQ: ROOT) from Embedded Insurance
Surfaces

* About MCD
* Advertising
* Contact Us
* Privacy Policy
* SEC Disclosure

FEATURED

T2 BIOSYSTEMS (NASDAQ: TTOO): FDA EXPECTATIONS AND SPECULATION AROUND THE ‘NEXT
MEMESTOCK’

Published

7 hours ago

August 22, 2023

Phillip Stein
Share
Tweet

T2 Biosystems, Inc. (NASDAQ: TTOO) has been attracting significant attention
throughout the tail end of July and August as investors eagerly await news
regarding the potential FDA approval of their Sepsis treatment. The company’s
stock price has surged by an impressive 320%, sparking intense speculation about
the possibility of further gains in the near term if the company delivers
positive news regarding their therapy.

The sentiment surrounding T2 Biosystems, Inc. is widely discussed across various
platforms such as Reddit and Twitter. Upon conducting further research, we have
identified numerous intriguing posts and threads that may warrant your
attention. In a general sense, many individuals perceive this company as a
potential candidate for the next “memestock,” drawing parallels to speculative
trading akin to gambling.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box
below.

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Within the aforementioned posts, there are noteworthy data points that merit
discussion. The initial catalyst for the surge in stock price appears to be the
hype generated around the earnings report. Remarkably, even after the earnings
release, the company’s stock has continued to climb, reaching a peak gain of
over 150%.

This aforementioned user speaks to the potential if the FDA were to grant
approval for the sepsis diagnosis. With price targets as high as $15 occurring
in moments. It is also believed that the adoption of this diagnostic tool in
hospitals across America and globally could generate billions in revenue. If
that were to happen, the user makes even more speculative price targets in the
triple digits.

According to the latest earnings, TTOO’s diagnostic technology stands without
peers, and the company has made significant strides, reducing its debt and
granting creditors ownership through shares. An extension on Nasdaq listing
requirements has been secured until November 20, and a breakthrough device
designation has been awarded for the candida auris diagnostic test. Moreover,
the stock equity program has been reinstated for new hires.

Furthermore, this user acknowledges the substantial trading volume and how
difficult it is to overlook the potential for a significant upswing in the near
future.

DIVING DEEPER ON TWITTER:

https://twitter.com/DPcert/status/1691151993698476032?s=20

As per insights shared by certain Twitter users, there seems to be a prevailing
expectation that FDA news will be disclosed sometime this week, with a
particular focus on tomorrow, August 23, 2023. This anticipation appears to be a
key driver behind the latest surge in the company’s stock price.

A Twitter user, going by the name of Deutsche Trader, boldly tagged Elon Musk in
a post related to the stock. Remarkably, this tweet has garnered nearly 35,000
impressions and 115 retweets as of the current moment. It’s worth noting that if
Musk were to comment on this stock, there could be significant consequences.
Nonetheless, Musk is widely recognized for his unconventional thinking and has,
on occasion, voiced his thoughts freely, irrespective of public sentiment.

QUICK OVERVIEW OF LAST EARNINGS:

T2 Biosystems, Inc. (NASDAQ: TTOO) recently announced its financial results for
Q2 2023, along with significant operational highlights:

Financial Highlights:

* Q2 total revenue was $2.0 million, primarily due to a decrease in BARDA
research contribution revenues.
* Sepsis test panel revenue reached $1.3 million, despite a $350 thousand
sepsis test backorder.
* Contracts for 11 T2Dx Instruments were executed during the quarter, including
international sales.
* A multi-year contract was secured for 7 T2Dx Instruments and sepsis test
panels in Poland.
* The company converted $10.0 million of term loan debt into equity,
strengthening its balance sheet.
* Cash and cash equivalents were $16.1 million as of June 30, 2023, with
additional proceeds raised through ATM sales in Q3.

Operational Highlights:

* The FDA granted Breakthrough Device Designation for the Candida auris
direct-from-blood molecular diagnostic test.
* Patient enrollment for the U.S. clinical trial for the T2Resistance Panel was
completed.
* An FDA submission was filed for the T2Biothreat™ Panel, which detects
biothreat pathogens.
* A clinical collaboration with Vanderbilt University Medical Center was
established to assess the T2Bacteria Panel’s impact on antibiotic usage.
* The company reported record quarterly sepsis test panel orders and the
second-largest sepsis-driven instrument order in its history.

Outlook:

* The company anticipates full-year total sepsis and related product revenue of
$9.5 million to $10.5 million, representing growth compared to 2022.

T2 Biosystems is a leader in the rapid detection of sepsis-causing pathogens and
antibiotic resistance genes, with a range of products powered by proprietary T2
Magnetic Resonance (T2MR®) technology. They have a robust pipeline of future
products, including the Candida auris test and T2Lyme™ Panel, aimed at improving
patient care and reducing healthcare costs.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily
to follow along!

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Disclosure: We have not been compensated for this article/video. MicroCap Daily
is not an investment advisor; this article/video does not provide investment
advice. Always do your research, make your own investment decisions, or consult
with your nearest financial advisor. This article/video is not a solicitation or
recommendation to buy, sell, or hold securities. This article/video is our
opinion, is meant for informational and educational purposes only, and does not
provide investment advice. Past performance is not indicative of future
performance.

Picture by sergeitokmakov from Pixabay

LEAVE A REPLY

CANCEL REPLY

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

FEATURED

NOVO INTEGRATED SCIENCES (NASDAQ: NVOS) GEARS UP FOR $57 MILLION RC NOTE
DISBURSEMENT

Published

1 day ago

August 21, 2023

Phillip Stein

ON TUESDAY, AUGUST 15, 2023, NOVO INTEGRATED SCIENCES, INC. (NASDAQ: NVOS)
RELEASED A SIGNIFICANT UPDATE REGARDING RECENT DEVELOPMENTS. FOLLOWING THIS
ANNOUNCEMENT, THE COMPANY’S VALUATION HAS SINCE SKYROCKETED AN IMPRESSIVE 200%.
THIS NEWS HAS SENT SHOCKWAVES THROUGH THE INVESTOR COMMUNITY, AND ITS IMPACT
CONTINUES TO INTENSIFY DURING INTRADAY TRADING ON MONDAY, AUGUST 21ST.

Allow us to dissect the announcement before delving into insights from the
retail community.

Advancements in SWAG Agreement: Novo is diligently working towards the
completion of the share purchase agreement, known as the “SWAG Agreement,” in
collaboration with SwagCheck Inc. (“SWAG”) and SWAG’s shareholders. This
agreement entails Novo’s acquisition of 100% of SWAG’s outstanding shares.
Furthermore, SWAG holds a unique right to acquire a valuable gem collection, as
specified in an agreement between SWAG and a Court-appointed Successor Receiver
for the United States District Court for the Central District of California. The
transaction is progressing with the aim of finalizing it in the near future.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box
below.

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Anticipated Initial Draw on $57,000,000 RC Note: Novo previously entered into a
securities purchase agreement with RC Consulting Group LLC, in favor of SCP
Tourbillion Monaco (referred to as the “Buyer”). This agreement involved the
issuance of an unsecured 15-year promissory note, known as the “RC Note,” to the
RC Noteholder. The RC Note, with a maturity date of April 26, 2038, amounts to
$70,000,000, comprising the $57,000,000 purchase price and an annual yield of
1.52% (non-compounding, zero coupon). Novo is soon expecting to receive an
initial disbursement from this $57,000,000.

Contemplation of Share Repurchase Program: Novo’s Board of Directors is
commencing a strategic review that includes the deliberation of a potential
share repurchase program.

Progress on GIMEG Project: Novo has secured a funding commitment of $40,000,000
from Sheikh Khaled bin Mohammad bin Fahad Al Thanayan via Gulf International
Minerals and Energy Group (GIMEG). This funding is earmarked for
project-specific joint ventures aimed at developing elder care and senior living
community facilities in Canada. Currently, the project is active and in its
preliminary stages of development and implementation.

THOUGHTS FROM THE RETAIL COMMUNITY:

We’ve come across an influential due diligence (DD) post on Reddit, which
provides an in-depth analysis of the company. It has garnered positive feedback
from fellow retail investors. You can check out the post by following this link:

https://www.reddit.com/user/goldmanspacs_/comments/15s699d/why_nvos_is_primed_to_be_the_next_ttoo/

A noteworthy section that deserves special attention is “The SWAG acquisition is
another big pending catalyst because they are required to have a financing
commitment of up to $90,000,000 to acquire them, and that direct investment of
$40Mil and $70mil Non-Dilutive debt helps them get there –

Again, the market cap at close today is around $15 Million, and with these multi
million agreements and potential revenue sources completed & on the way, the
potential for this to make a $TTOO type run is there.”

Another prominent user chimes in with apprehensions “I like the dd but stock is
currently up 40% in AH at .16 and there are warrants just above seems a bit
reckless here. Maybe you meant to post this .10-.11? Either way BoL but a little
too rich for me here.”

The initial user further points out that only the warrants priced at $0.50 are
officially registered, whereas the $0.17 and $0.18 ones remain unregistered and
therefore unusable by the company. In addition, the user emphasizes the future
potential, highlighting a $40 million investment and the possibility of $350
million in revenue, all while the company was valued at just $17 million.

Overall, both investors and management maintain an optimistic outlook regarding
the company’s future prospects. It’s crucial to highlight that NVOS must achieve
a share price of $1 by October to meet NASDAQ’s minimum bid price requirement,
with the possibility of a reverse stock split as a last resort.

We will update you on NVOS when more details emerge, subscribe to Microcapdaily
to follow along!

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Picture from Nature_Design by Pixabay

FEATURED

BLUE APRON HOLDINGS (NASDAQ: APRN) CHARTS PATH TO PROFITABILITY IN Q2 2023: DEBT
ELIMINATION AND STRATEGIC TRANSACTION

Published

4 days ago

August 18, 2023

Phillip Stein

Blue Apron (NYSE: APRN) is drawing heightened investor interest as its stock
continues to surge in intraday trading on August 18th, 2023. Remarkably, the
company has witnessed an impressive 94% increase in valuation this month alone,
with a significant 35% of this surge occurring today.

In conjunction with this remarkable market performance, Blue Apron has also
unveiled its financial outcomes for the second quarter of 2023, culminating on
June 30, 2023. Moreover, the company has successfully executed a strategic
transaction with FreshRealm, yielding the pivotal outcome of debt eradication
and the unveiling of a well-defined trajectory towards achieving adjusted EBITDA
profitability. The ensuing points encapsulate the key highlights from the
report:

Subscribe to Microcapdaily.com Right Now by entering your Email in the box
below.

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Financial Highlights:

* Net Revenue: The company reported net revenue of $106.2 million, showing a
sequential decrease of 6.1% and a year-over-year decrease of 14.5%. This
decrease was attributed to a one-time bulk sale to an enterprise customer in
the second quarter of 2022 and a planned reduction in marketing expenses.
* Customer Engagement: The company achieved record customer engagement metrics,
partly due to a price increase implemented in the second quarter of 2023.
* Average Order Value: The average order value increased by 12.7%
year-over-year and 7.7% sequentially.
* Average Revenue per Customer: The average revenue per customer increased by
21.3% year-over-year and 14.8% sequentially.
* Debt-Free Status: Blue Apron became debt-free, holding approximately $30.0
million in cash and cash equivalents as of June 30, 2023.
* Net Loss: The company reported a net loss of $61.9 million in the second
quarter, compared to a net loss of $23.3 million in the same period of the
previous year. Excluding one-time charges, the net loss was $13.3 million.
* Adjusted EBITDA Loss: Blue Apron improved its adjusted EBITDA loss, reporting
a loss of $2.6 million, a $13.6 million improvement from the previous year.
* Cash Usage: The company reduced net cash used in operating activities by 72%
year-over-year and 46% sequentially.

FreshRealm Transaction:

* The strategic transaction with FreshRealm, valued at up to $50.0 million,
involved selling operational infrastructure and entering into subleases for
fulfillment centers. FreshRealm became the exclusive supplier of Blue Apron’s
meal kits under a 10-year production and fulfillment agreement.
* The transaction included a $48.6 million one-time non-cash loss.
* Blue Apron received approximately $23.6 million of net cash proceeds from the
FreshRealm transaction’s closing and is eligible for up to $25.0 million in
additional value upon achieving certain milestones.

Future Outlook:

* The company expressed confidence in achieving its adjusted EBITDA
profitability goal and moving forward with its business plans following the
FreshRealm transaction.
* Blue Apron expects net revenue and customer count to be lower year-over-year
due to deliberate efforts to manage marketing spend and efficiency.
* The company anticipates achieving adjusted EBITDA profitability in the second
quarter of 2024.
* By the end of 2024, Blue Apron aims to achieve adjusted EBITDA profitability
and year-over-year revenue growth.

We will update you on APRN when more details emerge, subscribe to Microcapdaily
to follow along!

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Picture by geralt from Pixabay

FEATURED

PHENOMEX INC. (NASDAQ: CELL) TO MERGE WITH BRUKER CORPORATION IN STRATEGIC
ACQUISITION

Published

5 days ago

August 17, 2023

Phillip Stein

PhenomeX Inc. (NASDAQ: CELL) soars 136% as the company announced that they’re
finalizing a deal where Bruker Corporation will buy PhenomeX for $1.00 per share
in cash. This purchase values PhenomeX at around $108 million. PhenomeX is a
company that specializes in studying how individual cells work. They provide
tools for researchers to understand how cells function and how genes affect
their behavior.

PhenomeX was created in 2023 by merging two other companies, Berkeley Lights and
IsoPlexis. They currently have more than 400 of their research instruments in
use. These instruments help researchers study single cells using various tools
like software and chemicals. One of their main tools is the Beacon Optofluidic
system, which allows scientists to quickly analyze thousands of single cells at
once, helping them understand how cells function and relate to their genetic
makeup.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box
below.

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Dr. Mark R. Munch, the head of Bruker’s NANO Group, said that PhenomeX’s unique
tools are speeding up discoveries in cell biology research, which is important
for areas like making better medicines and therapies. This acquisition is a big
step for Bruker, helping them get into the field of studying single cells, which
matches their strategy of becoming a leader in new biology research methods.

The deal is expected to close by the end of 2023, as long as everything goes as
planned. Once the deal is done, PhenomeX will merge into a subsidiary of Bruker.
Any shares of PhenomeX that were not tendered in the tender offer will be
converted into the right to receive the same per-share consideration as paid in
the tender offer.

In simpler terms, if some shareholders decide not to sell their shares during
the offer, they won’t be left out. They will still receive the same price for
each share as those who did sell their shares. This ensures that all
shareholders are treated fairly and receive the same deal per share.

ABOUT PHENOMEX:

PhenomeX is focused on helping scientists better understand how cells work,
which could lead to improvements in health. They have tools that let researchers
study cells in detail and quickly, which is valuable for medical and biological
research.

ABOUT BRUKER CORPORATION:

Bruker makes high-tech instruments for scientific research. They work closely
with customers to develop tools that help scientists study things like cells,
molecules, and materials. They have a range of products for different research
areas, including biology, medicine, and industry.

We will update you on CELL when more details emerge, subscribe to Microcapdaily
to follow along!

SUBSCRIBE TO OUR 100% FREE PENNY STOCK NEWSLETTER. WE HAVE SOMETHING BIG COMING!

Subscribe Now

Picture by geralt from Pixabay

microcapdaily.com Open in urlscan Pro 35.197.12.90 Public Scan

Form analysis 11 forms found in the DOM

GET https://microcapdaily.com/

POST #

POST #

POST https://microcapdaily.com/wp-comments-post.php?wpe-comment-post=microcapdaily

POST #

POST #

POST #

POST #

POST #

POST #

POST #

Text Content

microcapdaily.com Open in urlscan Pro
35.197.12.90 Public Scan

Form analysis
11 forms found in the DOM